Electronic supplementary material
The online version of this article (doi:10.1186/1472-6947-12-60) contains supplementary material, which is available to authorized users.
Jürgen Kasper, Sascha Köpke contributed equally to this work.
CH has received grants from Biogen-Idec, Merck-Serono, Novartis Pharma and Teva Pharma as well as speaker’s fees. AS has received a board membership fee from Novartis and speaker’s fees from Sanofi-Aventis. SK is supported by a rehab-fellowship grant from the National MS Society, USA. JK and KF have received travel expenses from Merck Serono. IB has no conflict of interest.
Conceived and designed the experiments: JK, SK, CH, KF,NS. Performed the experiments: SK, KF, IB. Analysed the data: JK. Contributed reagents/materials/analysis tools: SK, IB, KF, NS,AS. Wrote the manuscript: JK, SK, CH, AS. All authors read and approved the final manuscript.
Patients making important medical decisions need to evaluate complex information in the light of their own beliefs, attitudes and priorities. The process can be considered in terms of the theory of planned behaviour.
Decision support technologies aim at helping patients making informed treatment choices. Instruments assessing informed choices need to include risk knowledge, attitude (towards therapy) and actual uptake. However, mechanisms by which decision support achieves its goals are poorly understood.
Our aim was therefore to develop and validate an instrument modeling the process of multiple sclerosis (MS) patients’ decision making about whether to undergo disease modifying (immuno-)therapies (DMT).
We constructed a 30-item patient administered questionnaire to access the elaboration of decisions about DMT in MS according to the theory of planned behaviour. MS-patients’ belief composites regarding immunotherapy were classified according to the domains “attitude”, “subjective social norm” and “control beliefs” and within each domain to either “expectations” or “values” yielding 6 sub-domains. A randomized controlled trial (n = 192) evaluating an evidence based educational intervention tested the instrument’s predictive power regarding intention to use immunotherapy and its sensitivity to the intervention.
The psychometric properties of the questionnaire were satisfactory (mean item difficulty 62, mean SD 0.9, range 0–3). Responses explain up to 68% of the variability in the intention to use DMT was explained by up to 68% in the total sample. Four weeks after an educational intervention, predictive power was higher in the intervention (IG) compared to the control group (CG) (intention estimate: CG 56% / IG 69%, p = .179; three domains CG 56% / IG 74%, p = .047; six sub-domains CG 64% / IG 78%, p = .073). The IG held more critical beliefs towards immunotherapy (p = .002) and were less willing to comply with social norm (p = .012).
The questionnaire seems to provide a valid way of explaining patients’ inherent decision processes and to be sensitive towards varying levels of elaboration. Similar tools based on the theory of planned behaviour could be applied to other decision making scenarios.